Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.44 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.44 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.42 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.58 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.49 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 1/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3084827 | 0.85 | PTGDR2 (0.56) | PTGDR2AKR1B10AKR1B1PTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL3084042 | 0.83 | PTGDR2 (0.56) | PTGDR2 | |
| Hydrochloric Acid SCHEMBL3081708 | 0.83 | BAZ2B (0.59) | PTGDR2AKR1B10AKR1B1AKR1A1PTGS1 | |
| Hydrochloric Acid SCHEMBL3085389 | 0.83 | KRAS (0.60) | PTGDR2AKR1B10AKR1B1AKR1A1PTGS1 | |
| Hydrochloric Acid SCHEMBL3544756 | 0.82 | PTGDR2 (0.46) | PTGDR2PTGS1PTGS2KRASBAZ2B | |
| SCHEMBL16381991 | 0.81 | BAZ2B (0.60) | PTGDR2AKR1B10AKR1B1AKR1A1KRAS | |
| SCHEMBL3084952 | 0.81 | PTGDR2 (0.47) | PTGDR2PTGS1PTGS2KRASBAZ2B | |
| Hydrochloric Acid SCHEMBL3081497 | 0.80 | HSD17B10 (0.43) | PTGDR2AKR1B10AKR1B1PTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL3096737 | 0.80 | PTGDR2 (0.58) | PTGDR2AKR1B10AKR1B1PTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL3094504 | 0.80 | KDM4E (0.65) | PTGDR2KDM4EMEN1GLACASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234396-A1 | Tetrhydropyridoindole Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-16 | — | — | US | disclosed |
| US-7714132-B2 | Tetrahydropyridoindole derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-05-11 | — | — | US | disclosed |
| EP-1725553-B1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | disclosed |
| EP-1725553-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005095397-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234396-A1 | Tetrhydropyridoindole Derivatives | TPH2, TPH1, HTR5A | PTGS1 1356/4885PTGS2 941/4885GLA 2818/4885 |
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | TPH2, TPH1, HTR2C | PTGS1 765/4885PTGS2 564/4885GLA 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.